(HealthDay News) — Among cancer survivors, excess body weight is associated with an increased risk of a second primary cancer, according to a study published in JAMA Network Open.

The US Food and Drug Administration (FDA) has approved a 420 mg dosage strength of Hercessi (trastuzumab-strf), a biosimilar to Herceptin (trastuzumab). Hercessi, a HER2/neu receptor antagonist, is ...

The FDA has approved Keytruda (pembrolizumab) in combination with chemotherapy as first-line treatment for adults with malignant pleural mesothelioma.

Moderately hypofractionated nodal radiotherapy is not inferior to normofractionated radiotherapy for early breast cancer, data suggest.

Research presented at ESMO 2024 could have practice-changing implications for breast, gastrointestinal, genitourinary, and gynecologic cancers.

Nivolumab plus ipilimumab can provide long-term benefits to patients with advanced melanoma, according to a 10-year update of the CheckMate 067 trial.

Virtual palliative care has similar effects on quality of life as in-person care for patients with advanced non-small cell lung cancer.

Source: Getty Images mRNA COVID-19 vaccines appear to increase PD-L1 expression across cancers, and this may explain the improved survival observed in vaccinated cancer patients receiving immune ...

Our easy-to-read fact sheets provide clinicians with reliable information to share with patients and their caregivers. Breast cancer is the most common cancer in women in the United States.